Bisantrene - Update Pharma

Drug Profile

Bisantrene - Update Pharma

Alternative Names: CL-216942; Cyabin; NSC-337766; Orange Crush; UPI-928; Zantrene

Latest Information Update: 20 Feb 2014

Price : $50

At a glance

  • Originator Wyeth Pharmaceuticals
  • Developer Update Pharma; Wyeth Pharmaceuticals
  • Class Aldehydes; Anthracenes; Antineoplastics; Cytostatic antibiotics; Hydrazones; Imidazoles; Small molecules
  • Mechanism of Action DNA modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Acute myeloid leukaemia; Cancer

Most Recent Events

  • 18 Feb 2014 Bisantrene - Update Pharma receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 18 Feb 2014 Investigation in Acute myeloid leukaemia in USA (IV)
  • 01 Aug 2013 Investigation in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top